Paper2334566
Estrogen and progesterone receptor analyses in more than 4,000 human breast cancer samples. A study with special reference to age at diagnosis and stability of analyses. Southern Swedish Breast Cancer Study Group.
Fernö M and 6 others. Acta Oncol, 1990. Cited by 51 papers, by iCite.
Cite this record
ConductScience Library. Estrogen and progesterone receptor analyses in more than 4,000 human breast cancer samples. A study with special reference to age at diagnosis and stability of analyses. Southern Swedish Breast Cancer Study Group. Papers, record 2334566. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/2334566
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
Estrogen and progesterone receptor analyses in more than 4,000 human breast cancer samples. A study with special reference to age at diagnosis and stability of analyses. Southern Swedish Breast Cancer Study Group.
- PubMed
Topics10
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Breast Neoplasms | Major topic |
| Receptors, Estrogen | Major topic |
| Receptors, Progesterone | Major topic |
| Adult | |
| Age Factors | |
| Aged | |
| Aged, 80 and over | |
| Female | |
| Humans | |
| Middle Aged |
Source PubMed
Cited by14
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 51 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 27386491 | The implication and potential applications of high-mobility group box 1 protein in breast cancer. | Ann Transl Med | 2016 | https://conductscience.org/library/papers/27386491 | PubMed |
| 27029552 | CYP1A2--a novel genetic marker for early aromatase inhibitor response in the treatment of breast cancer patients. | BMC Cancer | 2016 | https://conductscience.org/library/papers/27029552 | PubMed |
| 26472348 | Differences in clinical importance of Bcl-2 in breast cancer according to hormone receptors status or adjuvant endocrine therapy. | BMC Cancer | 2015 | https://conductscience.org/library/papers/26472348 | PubMed |
| 20308658 | Breast cancer among the oldest old: tumor characteristics, treatment choices, and survival. | J Clin Oncol | 2010 | https://conductscience.org/library/papers/20308658 | PubMed |
| 18945339 | Correlation of HER-2 over-expression with clinico-pathological parameters in Tunisian breast carcinoma. | World J Surg Oncol | 2008 | https://conductscience.org/library/papers/18945339 | PubMed |
| 17892570 | Pathobiological features of breast tumours in the State of Kuwait: a comprehensive analysis. | J Carcinog | 2007 | https://conductscience.org/library/papers/17892570 | PubMed |
| 15642173 | Histopathological features of breast tumours in BRCA1, BRCA2 and mutation-negative breast cancer families. | Breast Cancer Res | 2005 | https://conductscience.org/library/papers/15642173 | PubMed |
| 11866593 | A rationally designed genotoxin that selectively destroys estrogen receptor-positive breast cancer cells. | J Am Chem Soc | 2002 | https://conductscience.org/library/papers/11866593 | PubMed |
| 10811891 | Steroid hormones induce HMG1 overexpression and sensitize breast cancer cells to cisplatin and carboplatin. | Proc Natl Acad Sci U S A | 2000 | https://conductscience.org/library/papers/10811891 | PubMed |
| 8986764 | Synthesis and biological activity of DNA damaging agents that form decoy binding sites for the estrogen receptor. | Proc Natl Acad Sci U S A | 1996 | https://conductscience.org/library/papers/8986764 | PubMed |
| 8944331 | Improvement of quality control for steroid receptor measurements: analysis of distributions in more than 40000 primary breast cancers. French Study Group on Tissue and Molecular Biopathology. | Breast Cancer Res Treat | 1996 | https://conductscience.org/library/papers/8944331 | PubMed |
| 8443399 | Prognostic significance of flow cytometric DNA analysis and estrogen receptor content in breast carcinomas--a 10 year survival study. | Breast Cancer Res Treat | 1992 | https://conductscience.org/library/papers/8443399 | PubMed |
| 8386948 | Histologic types and hormone receptors in breast cancer in men: a population-based study in 282 United States men. | Cancer Causes Control | 1993 | https://conductscience.org/library/papers/8386948 | PubMed |
| 7579503 | Recurrence-free survival in breast cancer improved by adjuvant tamoxifen--especially for progesterone receptor positive tumors with a high proliferation. | Breast Cancer Res Treat | 1995 | https://conductscience.org/library/papers/7579503 | PubMed |
Genes2
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| EREG | 2069 | PubTator's text mining | https://conductscience.org/library/genes/2069 | NCBI Gene |
| PGR | 5241 | PubTator's text mining | https://conductscience.org/library/genes/5241 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/2334566
GET https://conductscience.org/api/papers/v1/2334566/authors